logo

Corcept Therapeutics Inc (CORT)



Trade CORT now with
  Date
  Headline
9/10/2020 8:41:45 AM Corcept Therapeutics Begins Second Phase 2 Trial Of Miricorilant To Treat Weight Gain Caused By Antipsychotic Medication
7/28/2020 8:39:47 AM Corcept Therapeutics Enrolls First Patient In GRADIENT Phase 3 Trial Of Relacorilant
9/18/2019 8:32:47 AM Corcept Therapeutics Names Kimberly Park To Board
10/1/2018 7:15:34 AM Corcept Therapeutics Receives Orphan Designation For Relacorilant As Treatment For Pancreatic Cancer
2/1/2018 8:40:32 AM Corcept Therapeutics Q4 Revenue $53.3 Mln Vs. $23.8 Mln Prior Year